Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; AGO Breast Study Group.

J Natl Cancer Inst. 2013 Jul 17;105(14):1018-26. doi: 10.1093/jnci/djt145. Epub 2013 Jul 16.

2.

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H.

Br J Cancer. 2010 Jan 19;102(2):301-15. doi: 10.1038/sj.bjc.6605498. Epub 2010 Jan 5.

3.

Estimating the mean and variance from the median, range, and the size of a sample.

Hozo SP, Djulbegovic B, Hozo I.

BMC Med Res Methodol. 2005 Apr 20;5:13.

4.

Recombinant erythropoietin in clinical practice.

Ng T, Marx G, Littlewood T, Macdougall I.

Postgrad Med J. 2003 Jul;79(933):367-76. Review.

5.

Erythropoietin, uncertainty principle and cancer related anaemia.

Clark O, Adams JR, Bennett CL, Djulbegovic B.

BMC Cancer. 2002 Sep 24;2:23.

6.

Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report.

Heatherington AC, Schuller J, Mercer AJ.

Br J Cancer. 2001 Apr;84 Suppl 1:11-6.

7.

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.

Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, Vansteenkiste JF, Rosso R, Ewers SB, Sundal E, Schatzmann E, Stocker H.

Br J Cancer. 1999 May;80(3-4):396-402.

8.
Items per page

Supplemental Content

Write to the Help Desk